Adaptate takeout is Takeda’s latest move in γδ sector

Already an early mover in the γδ therapeutics area, Takeda’s exercise of its option to acquire γδ antibody start-up Adaptate via another build-to-buy deal represents another step in the pharma’s evolution toward new modalities, beyond its historical strength in small molecules.

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) held the option to acquire Adaptate Biotherapeutics Ltd. for a fixed fee as part of an arrangement in which the biotech was spun out of GammaDelta Therapeutics Inc. in 2019. Terms of the buyout weren’t disclosed...